Interleukin-17

Healio spoke with Philip J. Mease, MD, about recent advancements in psoriatic arthritis.

DESTIN, Fla. — Incomplete understanding of axial spondyloarthritis disease process poses challenges for treatment decision making, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, discusses DICE Therapeutics’ phase 1 study of DC-806, a new oral interleukin-17A inhibitor, as an alternative to injectable medications in psoriasis treatment.

Biologic therapy persistence in psoriatic arthritis often depends on whether the drug was a first or second treatment, with depression, anxiety, older age and higher tender joint count also leading to discontinuation, according to data.

The interleukin-17 inhibitor izokibep has demonstrated positive safety and efficacy data at 46 weeks among patients with psoriatic arthritis, according to a press release from its manufacturer.

SCOTTSDALE, Ariz. — Understanding patients’ disease burden and priorities can help rheumatologists choose the best therapy for psoriatic arthritis, noted a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

The use of bimekizumab to inhibit both interleukin-17A and IL-17F was well-tolerated and impactful in improving axial spondyloarthritis outcomes across two phase 3 trials, according to data published in the Annals of the Rheumatic Diseases.

Correctly identifying cytokine pathways that are dysregulated in any given rheumatology patient could lead to better use of current biologic therapies, said a presenter at the 2022 Association of Women in Rheumatology annual conference.

Although a range of biologic options are available to clinicians treating psoriatic arthritis, it crucial to know which disease domains are involved as this will “dictate treatment,” according to a presenter at the Biologic Therapies Summit.